Independent Portfolio Consultants’s Vertex Pharmaceuticals VRTX Stock Holding History

Independent Portfolio Consultants’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-810	Closed	-$64K	–	765
2016 Q1	$64K	Sell	810 -2,405	-75%	-$218K	0.02%	541
2015 Q4	$405K	Buy	3,215 +210	+7%	+$25.4K	0.12%	234
2015 Q3	$313K	Sell	3,005 -610	-17%	-$78.4K	0.07%	298
2015 Q2	$446K	Buy	3,615 +309	+9%	+$38.9K	0.09%	265
2015 Q1	$390K	Buy	3,306 +1,191	+56%	+$143K	0.08%	274
2014 Q4	$251K	Sell	2,115 -3,440	-62%	-$387K	0.05%	334
2014 Q3	$624K	Buy	5,555 +880	+19%	+$83.8K	0.17%	178
2014 Q2	$443K	Buy	+4,675	New	+$328K	0.12%	273

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Independent Portfolio Consultants's VRTX Position: Q2 2016 in Review

Independent Portfolio Consultants sold out of Vertex Pharmaceuticals (VRTX) in Q2 2016, closing a stake of 810 shares — an estimated $64K sold.

Independent Portfolio Consultants first reported a position in VRTX in Q2 2014 and held it in 8 quarters. The position peaked at $624K in Q3 2014. 482 funds tracked by Wall St. Rank hold VRTX as of Q2 2016.

Independent Portfolio Consultants reported no remaining Vertex Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Independent Portfolio Consultants sold 810 Vertex Pharmaceuticals shares in Q2 2016, an estimated $64K.
Independent Portfolio Consultants first reported a position in Vertex Pharmaceuticals in Q2 2014 and held it in 8 quarters.
Independent Portfolio Consultants's Vertex Pharmaceuticals position peaked at $624K in Q3 2014.
482 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2016.

Based on Independent Portfolio Consultants's 13F filing for Q2 2016, filed 15 Jul 2016.